Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Tagliabue, Elda"'
Autor:
Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cosentino G; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Ciniselli CM; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., De Cecco L; Integrated Biology Platform, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cataldo A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Plantamura I; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., El-Abed S; Breast International Group (BIG), Brussels, Belgium., Wang Y; Novartis Pharma AG, Basel, Switzerland., Bajji M; Institute Jules Bordet (IJB), Brussels, Belgium., Nuciforo P; Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Huober J; Breast Center, Cantonal Hospital, St. Gallen, Switzerland., Ellard SL; BC Cancer, Kelowna, British Columbia, Canada., Rimm DL; Department of Pathology, Yale University School of Medicine, New Haven, Connecticut, USA., Gombos A; Institute Jules Bordet (IJB), Brussels, Belgium., Daidone MG; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Verderio P; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Cosimo S; Biomarkers Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Cancer medicine [Cancer Med] 2022 Jan; Vol. 11 (2), pp. 332-339. Date of Electronic Publication: 2021 Dec 17.
Autor:
Di Cosimo S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Triulzi T; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Pizzamiglio S; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., De Cecco L; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., de Azambuja E; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., Fumagalli D; Breast International Group (BIG)-aisbl, Bruxelles, Belgium., Putzai L; Yale Cancer Center, Yale School of Medicine, New Haven, USA., Harbeck N; Brustzentrum der Universität München (LMU), Munchen, Germany., Izquierdo M; Oncology Clinical Development, Oncology Business Unit, Novartis Pharma AG, Basel, Switzerland., Peña L; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Daidone MG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Huober J; University of Ulm, Ulm, Germany., Gori S; IRCCS Sacro Cuore-Don Calabria Hospital, Negrar, Verona, Italy., Cinieri S; Antonio Perrino Hospital, Brindisi, Italy., Torri V; IRCCS - Istituto di Ricerche Farmacologiche 'Mario Negri' Milano, Italy., Baselga J; Vall D'Hebron Institute of Oncology, Barcelona, Spain., Piccart M; Istitut Jules Bordet, Universitè Libre de Bruxelles, Belgium., de Braud FG; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Apolone G; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Verderio P; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy., Tagliabue E; Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. Electronic address: elda.tagliabue@istitutotumori.mi.it.
Publikováno v:
European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2019 Sep; Vol. 118, pp. 1-9. Date of Electronic Publication: 2019 Jul 05.
Autor:
Castagnoli L; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Iorio E; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Dugo M; Functional Genomics and Bioinformatics Core Facility, Department of Applied Research and Technology Development, Fondazione IRCCS Istituto Nazionale deiTumori, Milan, Italy., Koschorke A; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Faraci S; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Canese R; Core Facilities, NMR Unit, Istituto Superiore di Sanità, Roma, Italy., Casalini P; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Nanni P; Laboratory of Immunology and Biology of Metastasis, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy., Vernieri C; IFOM, FIRC Institute of Molecular Oncology, Milan, Italy.; Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Di Nicola M; Unit of Immunotherapy and Anticancer Innovative Therapeutics, Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morelli D; Laboratory Medicine Unit, Department of Pathology and Laboratory Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Pupa SM; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2019 Feb; Vol. 234 (2), pp. 1768-1779. Date of Electronic Publication: 2018 Aug 21.
Autor:
Giussani M; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Landoni E; Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Merlino G; Biomarkers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Turdo F; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Veneroni S; Tissue Biobank, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Paolini B; Anatomic Pathology A Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Cappelletti V; Biomarkers Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Miceli R; Medical Statistics, Biometry and Bioinformatics Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Orlandi R; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Triulzi T; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2018 Aug; Vol. 233 (8), pp. 6280-6290. Date of Electronic Publication: 2018 Mar 09.
Autor:
Triulzi T; Molecular Targeting Unit, Department of Experimental Oncology & Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Bianchi GV; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Tagliabue E; Molecular Targeting Unit, Department of Experimental Oncology & Molecular Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Publikováno v:
Future oncology (London, England) [Future Oncol] 2016 Jun; Vol. 12 (11), pp. 1413-28. Date of Electronic Publication: 2016 Mar 23.
Autor:
Tagliabue E; Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan 20133, Italy. elda.tagliabue@istitutotumori.mi.it, Campiglio M, Pupa SM, Balsari A, Ménard S
Publikováno v:
Journal of the National Cancer Institute. Monographs [J Natl Cancer Inst Monogr] 2011; Vol. 2011 (43), pp. 82-5.
Autor:
Berruti A; Oncologia Medica, Dipartimento di Scienze Cliniche e Biologiche, Università di Torino, Azienda Ospedaliera Universitaria San Luigi di Orbassano, Orbassano, Italy. alberto.bottini@email.it, Generali D, Kaufmann M, Puztai L, Curigliano G, Aglietta M, Gianni L, Miller WR, Untch M, Sotiriou C, Daidone M, Conte P, Kennedy D, Damia G, Petronini P, Di Cosimo S, Bruzzi P, Dowsett M, Desmedt C, Mansel RE, Olivetti L, Tondini C, Sapino A, Fenaroli P, Tortora G, Thorne H, Bertolini F, Ferrozzi F, Danova M, Tagliabue E, de Azambuja E, Makris A, Tampellini M, Dontu G, Van't Veer L, Harris AL, Fox SB, Dogliotti L, Bottini A
Publikováno v:
Journal of the National Cancer Institute. Monographs [J Natl Cancer Inst Monogr] 2011; Vol. 2011 (43), pp. 147-51.
Autor:
Lucci MA; Department of Experimental Pathology, University of Pisa, Pisa, Italy., Orlandi R, Triulzi T, Tagliabue E, Balsari A, Villa-Moruzzi E
Publikováno v:
Cellular oncology : the official journal of the International Society for Cellular Oncology [Cell Oncol] 2010; Vol. 32 (5-6), pp. 361-72.
Autor:
Giordano GG; Istituto di Anatomia Patologica, Facoltà di Medicina, II Università di Napoli, Napoli, Italy. giacomogiordano@libero.it, Tagliabue E, Pupa SM
Publikováno v:
Journal of cellular physiology [J Cell Physiol] 2004 Mar; Vol. 198 (3), pp. 343-9.
Autor:
Michael F. Press, Dennis J. Slamon, Joan S. Brugge, Sara A. Hurvitz, Jason J. Zoeller, Judy Dering, Laura M. Selfors
Publikováno v:
PLoS ONE
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
PloS one, vol 16, iss 5
PLoS ONE, Vol 16, Iss 5, p e0251163 (2021)
Our previous pre-clinical work defined BCL-2 induction as a critical component of the adaptive response to lapatinib-mediated inhibition of HER2. To determine whether a similar BCL-2 upregulation occurs in lapatinib-treated patients, we evaluated gen